PSCs have the ability to differentiate into any of the 220+ cell types found in the human body. This capability provides great potential for cell therapies, with a growing range of clinical applications.
Induced PSCs (iPSCs) can be generated by expressing specific transcription factor(s) in primary somatic cells, reverting the cells back into a pluripotent state.
We are firm believers of the potential of iPSC based therapies and have invested significant efforts and resources in enabling the manufacturing of cGMP grade materials derived iPSCs for our customers today and tomorrow.

See the opportunity in every challenge


Asset 2

We can help you address your key challenges in iPSC manufacturing and convert them into opportunities. Whether it is iPSC reprogramming or differentiation under cGMP, process control and characterization or efficient scale-up, we have a tailored solution.


Leverage established cGMP-grade iPSC capabilities


As the manufacturers of the world’s first reported GMP iPSC bank, we have extensive experience in cGMP pluripotent stem cell generation and banking.

We provide a full range of iPSC manufacturing services tailored to your needs.

With our extensive experience in cGMP manufacture and our innovative technology, we can help you improve your efficiency and speed to market.

We have the expertise to reprogram many different cell types such as human peripheral blood and mononuclear cells (PBMCs), dermal fibroblasts and CD34+ hematopoietic progenitor cells.


Rely on an established process


L7™ – 1 workflow, 7 components, 1 provider

Asset 3

Non-viral 4D-Nucleofector™ Transfection Technology is a key integral part for the reprogramming of cGMP grade iPSCs. With our cGMP iPSC manufacturing platform using the L7 cell culture system, you can rely on a proven, established process.


Perform directed differentiation into all three lineages


Asset 1

We have successfully generated specialized cells from human pluripotent stem cells in standard 2D cell culture system or computer-controlled 3D bioreactor
  • Ectodermal lineage
  • Endodermal lineage
  • Mesodermal lineage

What can this do for you?


Artboard 3 copy 11

So why choose our iPSC services?

  • World’s first iPSC GMP bank (2014) NIH
  • Master File readily available for cross reference with any sponsor’s filing
  • 8+ years of iPSC expertise, including research and development
  • Key opinion leadership through publications on iPSC manufacturing and characterization
  • E2E service offering
    • Phase appropriate assay and process development and qualification
    • Tissue acquisition
    • PSC reprogramming, expansion and differentiation (2D cell culture system and 3D computer-controlled bioreactors)
    • Fill & finish
    • Supply chain orchestration system through partnerships
  • Multiple cGMP customers working with PSC and iPSC cells
  • Proprietary L7 GMP platform services to enhance robustness
  • R&D team focused on further developing next generation GMP technologies

Download our latest iPSC platform literature

Human-Induced Pluripotent Stem Cells Manufactured Using a Current Good Manufacturing Practice-Compliant Process Differentiate Into Clinically Relevant Cells From Three Germ Layers– March 2018
March 2018
Computational fluid dynamics modeling, a novel, and effective approach for developing scalable cell therapy manufacturing processes – August 2019
End-to-End Platform for Human Pluripotent Stem Cell Manufacturing – December 2019
Long-Term Stability and Differentiation Potential of Cryopreserved cGMP-Compliant Human Induced Pluripotent Stem Cells – December 2019